New ULTRA Duramune vaccines provide a more comfortable vaccination experience for dogs Boehringer Ingelheim puts a cutting-edge perspective on vaccines with a revolutionary low-dose vaccine line that improves the overall vaccine experience for dogs.
ST. JOSEPH, Mo., Aug. 13, 2013 A new, revolutionary vaccine line is now available that contains the same vaccine protection you've come to expect against deadly pet diseases with 50 percent less volume per dose by using innovative improvements to the manufacturing process.
Boehringer Ingelheim Vetmedica, Inc,'s (BIVI) proprietary PureFil manufacturing processes are designed to reduce extraneous proteins and cellular debris in BIVI pet vaccines.
ULTRA Duramune is different from other vaccines on the pet market. Traditionally, pets received a 1 mL dose vaccine. Now, with the PureFil process, ULTRA Duramune vaccines were created to contain the same level of potency and disease protection with a 1/2 mL vaccine dose for a more comfortable vaccination experience.
"The first of its kind, ULTRA Duramune is a new vaccine line that improves the total vaccination experience for dogs by providing a vaccine with less volume per dose," says Dave Hustead, DVM, director, veterinary medical affairs, pet division, BIVI. "Now a pet owner can have the peace of mind that their pet is receiving the same disease protection they would receive from an equivalent 1ml vaccine, but now with 50% less volume for a more comfortable injection."
ULTRA Duramune provides the same high-level protection and defense as other Boehringer Ingelheim Vetmedica, Inc., vaccines with 50% less volume for more comfort for your dog.
Ask your veterinarian today for more information on ULTRA Duramune vaccines or visit www.BIVIULTRADuramune.com.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.
In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
SOURCE Boehringer Ingelheim